Full Breakdown
Controversy Surrounds FDA Claims on COVID-19 Vaccine Myocarditis Risks
12/6/2025, 6:02:03 AM
Allegations of Data Withholding by the Biden Administration
FDA Commissioner Marty Makary has alleged that the Biden administration withheld critical data regarding the risks of myocarditis associated with COVID-19 vaccines. In a recent interview, Makary stated, “Internal data submitted on myocarditis, we found that the Biden administration was sitting on data on myocarditis in young people, and it was not made public.” This assertion follows a memo from Dr. Vinay Prasad, the FDA’s top vaccine regulator, which claimed that at least 10 children died “after and because of receiving” the COVID-19 vaccine, suggesting a potential link to myocarditis.
Responses from Health Officials
The claims made by Makary have been met with strong opposition from other federal health officials. A senior official from the Biden administration labeled Makary's comments as “absurd,” asserting that there was no pressure from the White House to suppress adverse event reports. Dr. Ofer Levy, a member of the FDA’s advisory group, emphasized that data and briefing documents regarding vaccine safety were publicly accessible, stating, “I certainly didn’t see any secret information or cover-up in my experience working with the FDA.”
Context on Myocarditis and Vaccination
Myocarditis, an inflammation of the heart muscle, has been identified as a rare side effect of mRNA COVID-19 vaccines, particularly affecting males aged 12 to 29. A CDC report indicated that the incidence of myocarditis was 40.6 cases per million second doses administered to this demographic. However, the CDC and other health experts maintain that the benefits of vaccination outweigh the risks, especially considering that COVID-19 infection itself poses a higher risk of myocarditis.
Conflicting Reports on Vaccine Safety
Despite the FDA's recent claims, no confirmed deaths from myocarditis have been directly linked to the COVID-19 vaccines. A 2022 study found that the risk of myocarditis was seven times higher for individuals infected with COVID-19 compared to those who received the vaccine. Furthermore, most cases of vaccine-related myocarditis have been mild and resolved within days.
Criticism from Former FDA Leaders
Several former FDA commissioners have expressed concern over the new assertions regarding vaccine safety. In an editorial for The New England Journal of Medicine, they emphasized the importance of transparency and rigorous evidence in public health communications. They stated, “We are deeply concerned by sweeping new FDA assertions about vaccine safety and proposals that would undermine a regulatory model designed to ensure that vaccines are safe, effective, and available when the public needs them most.”
Conclusion: Ongoing Debate on Vaccine Risks
The controversy surrounding the FDA's claims highlights a significant divide in perspectives on vaccine safety and public health communication. While some officials assert that the risks of myocarditis are being downplayed, others emphasize the importance of vaccination in preventing severe outcomes from COVID-19. As the debate continues, the need for transparent and evidence-based discussions remains critical in maintaining public trust in health authorities.
Verbatim Quotes
- “We have done more to study myocarditis and to go back and look at deaths of people, of children from the Covid vaccine,” — Marty Makary, FDA Commissioner
- “There was no pressure coming from the White House,” — Senior Federal Health Official
- “Without question, the risk of myocarditis is vastly greater after infection than after vaccination,” — Dr. Mark Schleiss, Pediatric Infectious Diseases Professor
